LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease

Journal of Cardiac Failure ◽

10.1016/j.cardfail.2017.12.010 ◽

2018 ◽

Vol 24 (4) ◽

pp. 266-275 ◽

Author(s):

Yasunori Suematsu ◽

Wanghui Jing ◽

Ane Nunes ◽

Moti L. Kashyap ◽

Mahyar Khazaeli ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Cardiac Hypertrophy ◽

Rat Model ◽

Angiotensin Receptor ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease

Kidney Research and Clinical Practice ◽

10.23876/j.krcp.21.900 ◽

2021 ◽

Author(s):

In-Jeong Cho ◽

Seok-Min Kang

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Angiotensin Receptor ◽

Neprilysin Inhibitor ◽

Patients With Heart Failure ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease

Journal of Diabetes and its Complications ◽

10.1016/j.jdiacomp.2021.108056 ◽

2021 ◽

pp. 108056

Author(s):

Xingjian Zhang ◽

Yan Zhou ◽

Ruixia Ma

Keyword(s):

Kidney Disease ◽

Diabetic Kidney Disease ◽

Angiotensin Receptor ◽

Diabetic Kidney ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

Effect of LCZ696, a dual angiotensin receptor neprilysin inhibitor, on isoproterenol-induced cardiac hypertrophy, fibrosis, and hemodynamic change in rats

Cardiology Journal ◽

10.5603/cj.a2018.0048 ◽

2019 ◽

Vol 26 (5) ◽

pp. 575-583 ◽

Author(s):

Toru Miyoshi ◽

Kazufumi Nakamura ◽

Daiji Miura ◽

Masashi Yoshida ◽

Yukihiro Saito ◽

...

Keyword(s):

Cardiac Hypertrophy ◽

Hemodynamic Change ◽

Angiotensin Receptor ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

Protective effects of angiotensin-(1-7) administrated with an angiotensin-receptor blocker in a rat model of chronic kidney disease

10.1111/nep.12146 ◽

2013 ◽

Vol 18 (12) ◽

pp. 761-769 ◽

Author(s):

Chengyan Xu ◽

Wei Ding ◽

Minmin Zhang ◽

Yong Gu

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Rat Model ◽

Angiotensin Receptor Blocker ◽

Receptor Blocker ◽

Protective Effects ◽

Angiotensin Receptor

Download Full-text

The angiotensin receptor neprilysin inhibitor LCZ696 improves systolic cardiac function compared to angiotensin converting enzyme inhibition (ACEi) in a rat model of myocardial infarction

Heart Lung and Circulation ◽

10.1016/j.hlc.2015.06.258 ◽

2015 ◽

Vol 24 ◽

pp. S219

Author(s):

A. Kompa ◽

T. Weller ◽

T. von Lueder ◽

B. Wang ◽

H. Krum

Keyword(s):

Myocardial Infarction ◽

Angiotensin Converting Enzyme ◽

Cardiac Function ◽

Rat Model ◽

Angiotensin Converting Enzyme Inhibition ◽

Converting Enzyme ◽

Angiotensin Receptor ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Converting Enzyme Inhibition

Download Full-text

Angiotensin-receptor Blocker Therapy – Chronic Kidney Disease and Diabetes

European Cardiology Review ◽

10.15420/ecr.2006.0.2.1q ◽

2006 ◽

Vol 0 (2) ◽

pp. 1

Author(s):

Domenic A Sica ◽

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Angiotensin Receptor Blocker ◽

Receptor Blocker ◽

Angiotensin Receptor ◽

Blocker Therapy

Download Full-text

Faculty Opinions recommendation of The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717955094.793462652 ◽

2012 ◽

Author(s):

Chim Lang

Keyword(s):

Heart Failure ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Preserved Ejection Fraction ◽

Phase 2 ◽

Angiotensin Receptor ◽

Double Blind ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732240576.793542016 ◽

2018 ◽

Author(s):

Tahir Hussain

Keyword(s):

Chronic Kidney Disease ◽

Kidney Disease ◽

Ace Inhibitors ◽

Angiotensin Receptor Blockers ◽

Renin Angiotensin System ◽

Lower Mortality ◽

Angiotensin Receptor ◽

Angiotensin System ◽

Nationwide Study ◽

Receptor Blockers

Download Full-text

Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome

Life Sciences ◽

10.1016/j.lfs.2021.119692 ◽

2021 ◽

pp. 119692

Author(s):

Ying Li ◽

Li Kang ◽

Kai Rong ◽

Yue Zhang ◽

Ya Suo ◽

...

Keyword(s):

Cardiorenal Syndrome ◽

Protective Effects ◽

Angiotensin Receptor ◽

Neprilysin Inhibitor ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis

Indian Heart Journal ◽

10.1016/j.ihj.2021.01.002 ◽

2021 ◽

Author(s):

Pankaj Jariwala ◽

Arshad Punjani ◽

Harikishan Boorugu ◽

Dilip Babu Madhawar

Keyword(s):

Heart Failure ◽

Left Ventricular Ejection Fraction ◽

Left Ventricular ◽

Left Ventricular Ejection ◽

Outpatient Basis ◽

Angiotensin Receptor ◽

Ventricular Ejection Fraction ◽

Neprilysin Inhibitor ◽

Patients With Heart Failure ◽

Angiotensin Receptor Neprilysin Inhibitor

Download Full-text